Outcomes of fibrinolytic therapy for patients with metastatic cancer and acute pulmonary embolism.

Link to article at PubMed

Related Articles

Outcomes of fibrinolytic therapy for patients with metastatic cancer and acute pulmonary embolism.

Pulm Pharmacol Ther. 2019 Apr 05;:

Authors: Ogunbayo GO, Pecha R, Misumida N, Goodwin E, Ayoub K, Hillerson D, Elbadawi A, Abdel-Latif A, Elayi CS, Messerli AW, Smyth SS

Abstract
INTRODUCTION: Malignancy is a common cause of morbidity and mortality in the United States and around the world and the second leading cause of death in the United States. There is little data on the impact of metastatic cancer on the risk of hemorrhagic stroke or mortality among patients undergoing fibrinolytic therapy (FT) for acute PE.
METHODS: Using the National Inpatient Sample (NIS) database, we extracted admissions with a primary diagnosis of acute pulmonary embolism that underwent FT from 2010 to 2014. We performed a case control matched analysis between patients with and without metastatic cancer. Our primary outcome of interest was Mortality and our secondary outcome of interest was hemorrhagic stroke (HS).
RESULTS: Of the 883,183 patients with a primary diagnosis of acute PE between 2010 and 12014, 23,690 patients (2.7%) underwent FT. After exclusion, 22,592 patients were included in the analysis. Of these, 941 patients (4.2%) were reported to have metastatic cancer. There was a higher incidence of cerebrovascular accidents and intubation/mechanical ventilation in the metastatic cancer arm. Mortality was significantly higher in the metastatic cancer arm with no difference in the incidence of HS. In multivariate regression analysis, among all patients that underwent FT for acute PE, metastatic cancer was associated with a significant odds for mortality (OR 1.91, 95% CI 1.11-5.82, p < .001).
CONCLUSION: The presence of metastatic cancer in patients undergoing fibrinolytic therapy for acute pulmonary embolism is associated with increase mortality.

PMID: 30959093 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *